See more : NovelStem International Corp. (NSTM) Income Statement Analysis – Financial Results
Complete financial analysis of Acotec Scientific Holdings Limited (6669.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acotec Scientific Holdings Limited, a leading company in the Medical – Devices industry within the Healthcare sector.
- Mainz Biomed B.V. (MYNZ) Income Statement Analysis – Financial Results
- Saurashtra Cement Limited (SAURASHCEM.BO) Income Statement Analysis – Financial Results
- Clene Inc. (CLNN) Income Statement Analysis – Financial Results
- Stingray Group Inc. (STGYF) Income Statement Analysis – Financial Results
- The Tinplate Company of India Limited (TINPLATE.BO) Income Statement Analysis – Financial Results
Acotec Scientific Holdings Limited (6669.HK)
About Acotec Scientific Holdings Limited
Acotec Scientific Holdings Limited, a medical device company, researches and develops percutaneous transluminal angioplasty and drug-coated balloon products for the treatment of vascular diseases in Mailand China, Europe, and internationally. It offers AcoArt Orchid & Dhalia to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease; under clinical studies in nephrology for arteriovenous fistula stenosis and in neurology for vertebral atherosclerotic stenosis indications/applications; and under clinical studies in andrology for vasculogenic erectile dysfunction indications/applications. The company also provides AcoArt Tulip & Litos, which is under registration process in China and Europe, and under preclinical studies in the United States in vascular surgery for below-the-knee artery disease indications/applications; and in pre-clinical studies in andrology for vasculogenic erectile dysfunction indications/applications. The company was incorporated in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited is a subsidiary of CA Medtech Investment (Cayman) Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 473.85M | 395.55M | 303.81M | 193.98M | 124.91M |
| Cost of Revenue | 96.43M | 59.19M | 37.87M | 30.20M | 18.98M |
| Gross Profit | 377.42M | 336.35M | 265.94M | 163.78M | 105.93M |
| Gross Profit Ratio | 79.65% | 85.04% | 87.53% | 84.43% | 84.81% |
| Research & Development | 190.07M | 183.80M | 141.29M | 83.49M | 25.48M |
| General & Administrative | 83.78M | 87.85M | 99.22M | 20.01M | 8.17M |
| Selling & Marketing | 97.54M | 72.66M | 58.80M | 32.58M | 36.27M |
| SG&A | 181.32M | 160.51M | 158.02M | 52.59M | 44.44M |
| Other Expenses | -18.99M | -7.89M | -6.71M | 57.82M | 9.89M |
| Operating Expenses | 352.41M | 336.42M | 292.60M | 193.89M | 79.80M |
| Cost & Expenses | 448.84M | 395.61M | 330.48M | 224.09M | 98.78M |
| Interest Income | 18.51M | 20.26M | 4.73M | 41.00K | 49.00K |
| Interest Expense | 9.83M | 1.42M | 3.82M | 1.42M | 479.00K |
| Depreciation & Amortization | 46.26M | 19.44M | 12.40M | 5.36M | 3.90M |
| EBITDA | 70.54M | 91.17M | -51.02M | -24.66M | 29.87M |
| EBITDA Ratio | 14.89% | 23.13% | -17.93% | -12.44% | 23.91% |
| Operating Income | 25.01M | 72.08M | -64.19M | -29.49M | 25.97M |
| Operating Income Ratio | 5.28% | 18.22% | -21.13% | -15.20% | 20.79% |
| Total Other Income/Expenses | -10.56M | -1.76M | -3.05M | -1.96M | 3.38M |
| Income Before Tax | 14.45M | 70.32M | -67.24M | -31.45M | 26.71M |
| Income Before Tax Ratio | 3.05% | 17.78% | -22.13% | -16.21% | 21.38% |
| Income Tax Expense | -35.00K | 177.00K | 11.83M | 12.85M | 3.60M |
| Net Income | 14.49M | 70.14M | -79.08M | -44.29M | 23.11M |
| Net Income Ratio | 3.06% | 17.73% | -26.03% | -22.83% | 18.50% |
| EPS | 0.05 | 0.23 | -0.32 | -0.14 | 0.07 |
| EPS Diluted | 0.05 | 0.23 | -0.32 | -0.14 | 0.07 |
| Weighted Avg Shares Out | 301.08M | 299.61M | 247.12M | 313.39M | 313.39M |
| Weighted Avg Shares Out (Dil) | 301.08M | 299.61M | 248.07M | 313.39M | 313.39M |
Source: https://incomestatements.info
Category: Stock Reports